IL141943A0 - Modulation of endothelial cell surface receptor activity - Google Patents

Modulation of endothelial cell surface receptor activity

Info

Publication number
IL141943A0
IL141943A0 IL14194399A IL14194399A IL141943A0 IL 141943 A0 IL141943 A0 IL 141943A0 IL 14194399 A IL14194399 A IL 14194399A IL 14194399 A IL14194399 A IL 14194399A IL 141943 A0 IL141943 A0 IL 141943A0
Authority
IL
Israel
Prior art keywords
modulation
cell surface
endothelial cell
receptor activity
surface receptor
Prior art date
Application number
IL14194399A
Other languages
English (en)
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of IL141943A0 publication Critical patent/IL141943A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL14194399A 1998-09-11 1999-08-31 Modulation of endothelial cell surface receptor activity IL141943A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/152,160 US6248327B1 (en) 1998-09-11 1998-09-11 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
PCT/US1999/019965 WO2000015258A1 (en) 1998-09-11 1999-08-31 Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis

Publications (1)

Publication Number Publication Date
IL141943A0 true IL141943A0 (en) 2002-03-10

Family

ID=22541740

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14194399A IL141943A0 (en) 1998-09-11 1999-08-31 Modulation of endothelial cell surface receptor activity

Country Status (8)

Country Link
US (1) US6248327B1 (xx)
EP (1) EP1109578A4 (xx)
JP (1) JP2002524099A (xx)
AU (1) AU752649B2 (xx)
CA (1) CA2343220A1 (xx)
IL (1) IL141943A0 (xx)
NZ (1) NZ510450A (xx)
WO (1) WO2000015258A1 (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176289B1 (en) * 1998-09-11 2007-02-13 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
WO2001064750A2 (en) * 2000-03-01 2001-09-07 Vanderbilt University Modulation of the activity of the endothelial cel surface receptor ecrtp/dep-1 in the regulation of angiogenesis
AUPR598901A0 (en) * 2001-06-28 2001-07-19 Unisearch Limited Inhibition of angiogenesis by targeting protein tyrosine phosphatases
EP1585817B1 (en) 2002-02-20 2009-09-02 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
EP1490107A4 (en) * 2002-03-21 2005-11-09 Univ Florida MODULATION OF ANGIOGENESIS
AU2003225974A1 (en) * 2002-03-21 2003-10-08 California Institute Of Technology Modulation of angiogenesis through targeting of cysteine oxygenase activity
US20030194708A1 (en) * 2002-04-10 2003-10-16 Minke Binnerts Human homolog of crossveinless materials and methods
CA2503736A1 (en) * 2002-11-26 2004-06-10 Cold Spring Harbor Laboratory Dep-1 receptor protein tyrosine phosphatase interacting proteins and related methods
AU2005249381A1 (en) * 2004-04-23 2005-12-15 Amgen Inc. Antibodies of angiogenesis inhibiting domains of CD148
CA2561861A1 (en) * 2004-04-23 2005-12-15 Amgen Inc. Antibodies to angiogenesis inhibiting domains of cd148
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
US9216212B2 (en) 2005-08-05 2015-12-22 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
EP2002261A4 (en) * 2006-03-31 2009-04-08 Karima Ferrani-Kile METHOD AND COMPOSITIONS FOR OBTAINING AND APPLYING BIOLOGICALLY ACTIVE MULTIPROTEIN COMPLEXES
WO2010039224A2 (en) * 2008-09-30 2010-04-08 University Of Massachusetts Medical School Respiratory syncytial virus (rsv) sequences for protein expression and vaccines
WO2011038139A1 (en) 2009-09-23 2011-03-31 Amgen Inc. Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane
AU2012275346B2 (en) 2011-06-29 2016-03-17 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69110034T2 (de) 1990-03-14 1995-10-05 Washington Res Found Methoden und zusammensetzungen zur behandlung von bösartigen entartungen, die in zusammenhang mit einer proteinkinase stehen.
US5595911A (en) 1990-03-14 1997-01-21 Cold Spring Harbor Laboratory Isolation of a cDNA encoding a protein tyrosine phosphatase which localizes to focal adhesions
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
DE69530261T3 (de) 1994-05-03 2008-07-03 Cold Spring Harbor Laboratory Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
US5912138A (en) 1996-07-25 1999-06-15 Cold Spring Harbor Laboratory Substrate trapping protein tyrosine phosphatases
AU8479498A (en) 1997-07-08 1999-02-08 Cold Spring Harbor Laboratory Dual specificity phosphatase and methods of use

Also Published As

Publication number Publication date
CA2343220A1 (en) 2000-03-23
AU752649B2 (en) 2002-09-26
NZ510450A (en) 2003-12-19
US6248327B1 (en) 2001-06-19
JP2002524099A (ja) 2002-08-06
EP1109578A4 (en) 2004-03-31
AU5797799A (en) 2000-04-03
WO2000015258A1 (en) 2000-03-23
EP1109578A1 (en) 2001-06-27

Similar Documents

Publication Publication Date Title
IL141943A0 (en) Modulation of endothelial cell surface receptor activity
EP1140086A4 (en) N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS
GB2323700B (en) Electrochemical cells
EP1012590A4 (en) IMPROVED ELECTROCHEMICAL CELL
IL138267A0 (en) Upper body support
GB9805214D0 (en) Cell adhesion
EP0973866A4 (en) ADENOVIRUS E1-COMPLEMENTING CELL LINES
IL141471A0 (en) Regulation of substrate activity
GB9900396D0 (en) Arrangements of electrochemical cells
GB9719965D0 (en) Modified bioreactor
HUP0105168A3 (en) Transplantation of haematopoietic cells
HK1024721A1 (en) Epidermal cell growth activating material
GB2348047B (en) Electrochemical cells
AU1618500A (en) Human cell surface receptor proteins
GB9900398D0 (en) Arrangements of electrochemical cells
GB9820532D0 (en) Modified bioreactor
IL120445A0 (en) Biosensor for cells
AU3989801A (en) Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
AU7830500A (en) Modulation of ige receptor cell surface expression
GB9805572D0 (en) Improvements relating to support slings
GB9917180D0 (en) Cell surface receptor
GB9702350D0 (en) Utility surface
GB2327585B (en) Surface construction
EP1107774A4 (en) RAMP2a: RECEPTOR ACTIVITY MODIFYING PROTEIN-2a
GB9708586D0 (en) Hydrodynamic electrode cell